The New Alzheimer’s Drug: What is Kisunla?

On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other new Alzheimer’s medicines.
Zoom In on Dementia & Alzheimer's is a monthly virtual discussion series with world-class expert research scientists to keep you informed about the latest breakthroughs and findings in the field-from treatments and genetics to risk reduction, supplements, and more. Subscribe now for the latest expert information bout Alzheimer's disease and dementia.
#alzheimers #alzheimer #alzheimersdisease #dementia #caregiving #neurodegenerativedisease #neuroscience #Kisunla #Donanemab #AlzheimersMedication